LUCENCE/A*STAR
Molecular diagnostics company Lucence and the Agency for Science, Technology and Research (A*STAR) today announced study results indicating that the reagent used in Lucence’s SAFER Sample saliva collection kit inactivates SARS-CoV-2 within 45 seconds of sample collection. This proprietary reagent also stabilizes viral RNA at room temperature for up to one week. Together, these properties enable accessible, non-invasive, and safe sample collection via saliva, which is critical to scaling cost-effective testing worldwide. The reagent used in Lucence’s SAFER Sample kit was invented at A*STAR’s Institute of Bioengineering and Nanotechnology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005320/en/
The SAFER Sample Collection Kit is registered as a Class A medical device with the Health Sciences Authority of Singapore and is an easy-to-use saliva collection kit that comes with a bottle of stabilization fluid to be mixed with the sample at the point of collection, keeping viral RNA stable at room temperature for up to one week. While conventional viral transport media requires cold-chain transport to prevent sample degradation, which can drive up associated costs and limit testing geography, SAFER Sample’s proprietary media means samples can be transported to a lab without the need for chilling.
In this new study, Lucence and A*STAR demonstrated that the proprietary reagent provided with the SAFER Sample kit also achieved complete inactivation of SARS-CoV-2 virus within 45 seconds of exposure. Conventional viral transport media used for collecting nasal and nasopharyngeal swab specimens do not inactivate viral samples, creating risk of exposure to active virus during transportation from collection sites to the laboratory and higher costs associated with biohazard handling procedures. SAFER Sample kit’s viral inactivation capabilities could mean enhanced safety and reduced risk of exposure for any individual involved in the collection, transport, and testing processes. Lucence worked with the Diagnostics Development (DxD) Hub of A*STAR to evaluate the virucidal properties of the SAFER Sample reagent. Duke-NUS Medical School was also engaged to perform the virucidal work with SARS-CoV-2 virus.
Mass testing and screening of large populations is key to reduce the risk of COVID-19 transmission, morbidity and mortality. By eliminating obstacles to sample integrity and, now, biosafety through viral inactivation, the SAFER Sample kit could expand testing geography, decrease associated costs, and increase efficiency of testing at scale compared to approaches utilizing conventional viral transport media.
Studies with clinical partners are ongoing to further evaluate the performance of the SAFER Sample kit. With the support of DxD Hub in verification and validation, quality management system (QMS), and regulatory registration, Lucence has received ISO13485:2016 certification for its QMS which controls the processes for the manufacture of the SAFER Sample Saliva Specimen Collection Kit.
About Lucence
Lucence is a precision oncology company that makes state-of-the-art, highly sensitive liquid biopsy tests for disease detection and treatment selection. Lucence is headquartered in Palo Alto and Singapore, and its services are delivered worldwide through an accredited central laboratory. Visit www.lucence.com for more information.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency, spearheading economic-oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg . For information on the Diagnostics Development (DxD) Hub, visit https://www.a-star.edu.sg/accelerate/innovation-offerings/diagnostics-development-hub
Follow us on Facebook | LinkedIn | Instagram | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 21:36:00 CET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom